CA
NZ
UK
AU
IND
US
Despite this growth, Paxman AB (publ) (OTC: PXMBF) continues to grapple with a net margin of -1.4%, signaling potential challenges in maintaining profitability. Such performance raises questions for investors regarding the sustainability of revenue increases against operational costs. The lack ofEarnings Per Shareimprovement compared …
This development, finalized on August 19, 2026, positions Apimeds toCapitalizeon the growingDemandfor Apitox in Korea, particularly in specialized clinical settings. As part of the assignment agreement with FreeT Inc. Apimeds Pharmaceuticals US, Inc. (AMEX: APUS) has secured one hundred percent (100%) of the rights …
Elutia Inc. (NASDAQ: ELUT) has successfully completed the sale of its SimpliDerm business to Cellution Biologics Inc. for total proceeds potentially reaching $11 million. The transaction, which closed on August 17, 2026, includes approximately $7.7 million delivered to Elutia immediately, with additional contingent payments …
Moderna Inc. (NASDAQ: MRNA) is a leading biotechnology company with a marketCapitalizationof $25.1 billion, specializing in mRNA technology. Recently, the firm's share price soared 129% week-on-week after it achieved groundbreaking results in a clinical trial for its melanoma therapy in collaboration with Merck. The …
Starling Oncology, Inc. has entered into a new credit agreement enabling it to access a revolving line of credit facility totaling up to $25 million. This agreement aims to provide the company with additional financial flexibility, essential for managing its operational needs and enhancing …
This tender offer signifies a direct response to the support of its investors as Arbutus seeks to leverage its financial gains.
Alpha Teknova reported record second-quarterRevenueof $12.2 million, an 18% year-over-year increase, and raised its full-year revenue guidance to between $45 million and $47 million. This upward revision signals momentum in biopharma funding and custom solution offerings, which could attract investor interest.Key HighlightsSecond-quarter revenue of …
Dr. Ronald Primas embodies a modern approach to health focused on longevity, incorporating strategies built on preventive medicine principles. He works as a concierge doctor in New York City, often managing patient appointments late into the night. Primas integrates daily exercise into his busy …
Telix Pharmaceuticals Limited (NASDAQ: TLX) shares closed down 9% at $11.33 despite reporting 1H revenue of $477 million as adjusted EBITDA surged 146% to $52 million.
Seres Therapeutics, Inc. (NASDAQ: MCRB) pivoted to a Q2 net profit of $4.6 million from a prior $19.9 million deficit, primarily fueled by a $25 million gain tied to VOWST and reduced overhead.
Please wait processing your request...